Correction: Natural Products as a Source of Inspiration for Novel Inhibitors of Advanced Glycation Endproducts (AGEs) Formation

Planta Medica ◽  
2021 ◽  
Author(s):  
Stefaniya Velichkova ◽  
Kenn Foubert ◽  
Luc Pieters
Planta Medica ◽  
2021 ◽  
Author(s):  
Stefaniya Velichkova ◽  
Kenn Foubert ◽  
Luc Pieters

AbstractProtein glycation, a post-translational modification found in biological systems, is often associated with a core defect in glucose metabolism. In particular, advanced glycation endproducts are complex heterogeneous sugar-derived protein modifications implicated in the progression of pathological conditions such as atherosclerosis, diabetic complications, skin diseases, rheumatism, hypertension, and neurodegenerative diseases. Undoubtedly, there is the need to expand the knowledge about antiglycation agents that can offer a therapeutic approach in preventing and treating health issues of high social and economic importance. Although various compounds have been under consideration, little data from clinical trials are available, and there is a lack of approved and registered antiglycation agents. Next to the search for novel synthetic advanced glycation endproduct inhibitors, more and more the efforts of scientists are focusing on researching antiglycation compounds from natural origin. The main purpose of this review is to provide a thorough overview of the state of scientific knowledge in the field of natural products from plant origin (e.g., extracts and pure compounds) as inhibitors of advanced glycation endproduct formation in the period between 1990 and 2019. Moreover, the objectives of the summary also include basic chemistry of AGEs formation and classification, pathophysiological significance of AGEs, mechanisms for inhibiting AGEs formation, and examples of several synthetic anti-AGEs drugs.


Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 564
Author(s):  
Haruki Watanabe ◽  
Myoungsun Son

The disruption of the immune tolerance induces autoimmunity such as systemic lupus erythematosus and vasculitis. A chromatin-binding non-histone protein, high mobility group box 1 (HMGB1), is released from the nucleus to the extracellular milieu in particular environments such as autoimmunity, sepsis and hypoxia. Extracellular HMGB1 engages pattern recognition receptors, including Toll-like receptors (TLRs) and the receptor for advanced glycation endproducts (RAGE). While the HMGB1-RAGE axis drives inflammation in various diseases, recent studies also focus on the anti-inflammatory effects of HMGB1 and RAGE. This review discusses current perspectives on HMGB1 and RAGE’s roles in controlling inflammation and immune tolerance. We also suggest how RAGE heterodimers responding microenvironments functions in immune responses.


Heliyon ◽  
2020 ◽  
Vol 6 (11) ◽  
pp. e05364
Author(s):  
Isabella M. Atzeni ◽  
Jeltje Boersema ◽  
Hendri H. Pas ◽  
Gilles F.H. Diercks ◽  
Jean L.J.M. Scheijen ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0180092 ◽  
Author(s):  
Lisa Wolf ◽  
Christian Herr ◽  
Julia Niederstraßer ◽  
Christoph Beisswenger ◽  
Robert Bals

Sign in / Sign up

Export Citation Format

Share Document